The deconstruction of cellulose is essential for the conversion of biomass into fuels and chemicals. But cellulose, the most ...

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, announced ...

The festival, called The Arcades, is billed as “an undergraduate collage of music.” It began as a two-part course in UCSD’s ...

The Choose Europe for Science program will invest more than half a billion dollars between 2025 and 2027 to recruit ...

A Phase I trial involving ten patients with relapsed or refractory classical Hodgkin lymphoma or T-cell lymphoma has achieved a 100% overall response rate and a 50% complete remission rate, in ...

Researchers show that glycoRNAs, uncovered by the lab of Nobel Laureate, Carolyn Bertozzi, can be used to fight cancer.

In an era of rapidly advancing technologies, the role of critical and emerging technologies (CETs) in strengthening national ...

Carbyne, a one-dimensional chain of carbon atoms, is incredibly strong for being so thin, making it an intriguing possibility ...

Researchers from the Sant Pau Research Institute (IR Sant Pau), in collaboration with Sant Pau Hospital and the Josep Carreras Leukaemia Research Institute, have developed an innovative CAR-T cell ...

Gubra releases its results for the first quarter of 2025. The key development in the quarter was the out-licensing agreement to AbbVie for our anti-obesity asset GUBamy (Amylin). A landmark deal ...

Today, Gubra releases its results for the first quarter of 2025. The key development in the quarter was the out-licensing agreement to AbbVie for our anti-obesity asset GUBamy (Amylin). A landmark ...